NKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2025)
SANTA ANA, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) ('NKGen' or the 'Company'), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ('NK') cell therapeutics, today announced that Paul Y. Song, M.D., Chairman and Chief Executive Officer of NKGen, will present at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders ('AD/PD™ 2025') taking place online and in Vienna, Austria from April 1 – 5, 2025.
AD/PD™ 2025 is a premier event bringing together top international experts to discuss the latest advancements in Alzheimer's and Parkinson's research, clinical trials, and treatments. With over 4,700 participants from 70+ countries and 2,250 abstracts in 2024, it offers a platform for groundbreaking discoveries from the leading experts in the field.
Presentation Details:
Title:
Preliminary Cognitive Improvement in Phase 1 Cohort of Moderate Alzheimer's Disease Subjects Treated with Autologous Natural Killer Cells (Troculeucel; SNK01)
Session Name:
7540 – Advances in AD Drug Development 02
Session Type:
Symposium
Presentation Date:
Saturday, April 5, 2025, at 5:10 pm – 5:25 pm CEST
Room:
Hall E
Dr. Song's presentation will focus on the three-month cognitive and biomarker results from the Phase 1 cohort of the Phase 1/2a clinical trial for troculeucel NK cell therapy in moderate Alzheimer's disease, as well as new data from the six-month analysis of this cohort.
Previously disclosed data for troculeucel in Alzheimer's disease and solid tumors can be found on the Scientific Publications page of the Company's website at https://nkgenbiotech.com/scientific-publications/. News releases containing troculeucel clinical trial updates and regulatory approvals can be found on the News page of the Company's website at https://nkgenbiotech.com/news/.
About TroculeucelTroculeucel is a novel cell-based, patient specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate. NKGen is developing troculeucel for the treatment of neurodegenerative disorders and a broad range of cancers. Troculeucel is the International Nonproprietary Name ('INN') for SNK01 assigned by the World Health Organization ('WHO'). The WHO INN approval of troculeucel establishes a universally recognized nonproprietary drug name for SNK01 and marks a significant step on NKGen's journey toward bringing this therapy to market.
About NKGen BiotechNKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is headquartered in Santa Ana, California, USA. For more information, please visit www.nkgenbiotech.com.
Forward-Looking Statements Statements contained in this press release may contain 'forward-looking statements' within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as 'anticipate', 'believe', 'could', 'continue', 'expect', 'estimate', 'may', 'plan', 'outlook', 'future' and 'project' and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Because such statements are subject to risks and uncertainties, many of which are outside of the Company's control, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the Company's plans and expected timing for developing troculeucel and SNK02, including the expected timing of completing and announcing further results from its ongoing clinical studies; and the Company's expected timing for developing its product candidates and potential benefits of its product candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: the Company's ability to execute its plans and strategies; risks related to performing clinical studies; the risk that initial and interim results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available; potential delays in the commencement, enrollment and completion of clinical studies and the reporting of data therefrom; the risk that studies will not be completed as planned; the risk that the abstract will not be published as planned including delays in timing, format, or accessibility; and NKGen's ability to raise additional funding to complete the development of its product candidates. These and other risks and uncertainties are described more fully under the caption 'Risk Factors' and elsewhere in the Company's filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission's website at www.sec.gov and on the Company's website under the subheading 'Investors—Financial and Filings'. Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Internal Contact:Denise Chua, MBA, CLS, MLS (ASCP)SVP, Corporate Affairs949-396-6830dchua@nkgenbiotech.com
External Contacts:Kevin GardnerManaging DirectorLifeSci Advisors, LLCkgardner@lifesciadvisors.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
28bio Announces Nexon™ Neurotechnology Platform Powered by Engineered Human Brains
Exhibits complex neurological processes—including memory, learning, and cognition—and predicts human outcomes in preclinical drug development NEW ORLEANS, June 9, 2025 /PRNewswire/ -- 28bio today announced the Nexon™ neurotechnology platform—a major advancement in understanding human brain function. The platform integrates tissue engineering, neural interfacing and AI to engineer human brains at-scale and replicate complex neurological processes. The Nexon™ platform is now being used to improve the prediction of therapeutic efficacy and toxicity in humans, with several of the world's largest pharma companies already integrating Nexon™ into their drug development workflows. The Nexon™ platform also incorporates Organoid Intelligence (OI). The growing field of OI combines human brain organoids with brain-machine interfaces to model memory, learning, and cognition in vitro, offering novel functional cognitive biomarkers with the potential to reshape drug development in neurodegenerative disorders including Alzheimer's disease. Neurological drug development faces some of the highest failure rates in the pharmaceutical industry, due to poor translatability of animal models. Despite promising preclinical study results, many therapies ultimately fail in humans—contributing to a growing neurological health crisis and need for more predictive, human-relevant models. "We engineer human brains capable of elucidating the complexity of neurological processes and produce predictive data needed to change the trajectory of neurological drug development," said Alif Saleh, CEO of 28bio. "Industry and regulators are urgently asking for solutions to develop better neurological drugs faster and cheaper." About 28bio28bio is a neurotechnology company engineering human brains at-scale exhibiting memory, learning, and cognitive functions. Its Nexon™ platform integrates tissue engineering, neural interfacing, and AI to reverse today's neurological health crisis by improving the ability to predict which therapies will work in humans. 28bio is committed to advancing ethical standards in the development of brain organoid technology and engineered human cognition. For more information, visit View original content to download multimedia: SOURCE 28bio Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
3 hours ago
- Yahoo
From Campus To Careers: Landing Your First Job
The diplomas are signed, sealed, and delivered, but for the class of 2025, the real test begins: landing that first job. says it takes up to 20 applications to get one interview, and up to 15 interviews to get a job offer. While a bachelor's degree offers a significant financial advantage, new data shows graduates earn over $625 more per week. But it takes more than just a piece of paper to land the job. The tassel has been tossed, the diplomas are in hand, and for the class of 2025, the real work begins. According to a mix of hard and soft skills are consistently in high demand. Hard skills like marketing, presentation abilities, computer literacy, foreign language proficiency, and research capabilities provide a foundation. But career experts say it's often the soft skills that truly distinguish candidates. 'You need to be an effective communicator. You need to be an effective collaborator. You need to critically think,' said Flo Brett, Effective Leadership Academy Hiring managers consistently seek evidence of critical thinking, the ability to analyze information, and solve problems effectively. Active listening, fully focusing on the speaker, is also crucial. And in today's fast-paced work environment, time management, leadership potential, the capacity for teamwork, and adaptability are highly prized. So, while those in-demand soft skills can be the difference-maker in landing that first job, the field of study still plays a significant role in earning potential. According to the National Association of Colleges and Employers, engineering graduates are projected to command the highest average starting salary this year, at $76,000, followed closely by those in computer science, with a starting salary of $74,000. This is a developing story. Check back for updates as more information becomes available. Download the FREE Boston 25 News app for breaking news alerts. Follow Boston 25 News on Facebook and Twitter. | Watch Boston 25 News NOW
Yahoo
5 hours ago
- Yahoo
Summer solstice
By Kathy Farley Submitted to Corner Post You've heard the word solstice mentioned, but do you know what it means? There's one coming up soon, so let's review. The word solstice is roughly translated as 'sun standing still' because its movement appears to pause before reversing its path. A solstice occurs twice each year — when the Earth's tilt toward the sun is at a maximum (summer) and minimum (winter). When this takes place in the northern hemisphere in June, the sun reaches its northernmost and highest elevation, and we enjoy our longest day of the year (in terms of daylight hours). Conversely, when the winter solstice occurs in December, the opposite holds true. Interestingly, in the southern hemisphere conditions of the summer and winter solstices are reversed! As we are heading into warmer days of summer, and coming up on the longest day of 2025, our counterparts in South America and Australia are preparing for colder weather and their shortest day. Northern hemisphere summers are warmer than the winters, but winters in the southern hemisphere are warmer than summers. For residents in this region, summer solstice will occur at approximately 9:42am on Friday, June 20. The daylight hours on that day will be 5 hours and 38 minutes longer than on December 20, 2025 (the winter solstice). Because an astronomical year is actually 365.25 days long, the summer solstice can occur as early as June 20 or as late as June 22.
